• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/19/21 8:02:11 AM ET
    $MGEN
    Medical Specialities
    Health Care
    Get the next $MGEN alert in real time by email
    SC 13G 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. _ )*

                

    VIRIDIAN THERAPEUTICS, INC.


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    92790C104


    (CUSIP Number)

    February 09, 2021


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [ ] Rule 13d-1(b)
    [X] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. 92790C104

    1. NAMES OF REPORTING PERSONS

    Hawkes Bay Master Investors (Cayman) L.P.
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 363,284
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 363,284
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    363,284
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.97%
    12. TYPE OF REPORTING PERSON

    PN

    Item 1.
    (a) Name of Issuer
    VIRIDIAN THERAPEUTICS, INC.
    (b) Address of Issuer's Principal Executive Offices
    6200 Lookout Rd.
    Boulder, CO 80301
    Item 2.
    (a) Name of Person Filing
    Hawkes Bay Master Investors (Cayman) L.P.
    (b) Address of Principal Business Office or, if None, Residence
    c/o Wellington Management Group LLP
    280 Congress Street
    Boston, MA 02210
    (c) Citizenship
    Cayman Islands
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    92790C104
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [ ] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    If this statement is filed pursuant to Rule 13d-1(c), check this box [X]
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    The percentages reported in this Schedule 13G are based upon 5,213,006 shares of common stock outstanding.
    (b) Percent of Class:
    6.97%
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 0
    (ii) shared power to vote or to direct the vote 363,284
    (iii) sole power to dispose or to direct the disposition of 0
    (iv) shared power to dispose or to direct the disposition of 363,284
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    Not Applicable
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    Not Applicable.
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable.
    Item 9. Notice of Dissolution of Group.

    Not Applicable.
    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    By: Hawkes Bay Master Investors (Cayman) L.P.

    By: Wellington Alternative Investments LLC
    Its General Partner
    By: /s/ Matthew N. Shea
    Name: Matthew N. Shea
    Title: Authorized Person
    Date: February 19, 2021

    Get the next $MGEN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MGEN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by L Joseph Turner

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    2/8/21 5:41:03 PM ET
    $MGEN
    Medical Specialities
    Health Care

    SEC Form 4 filed by Evan Peter Harwin

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    2/8/21 5:40:19 PM ET
    $MGEN
    Medical Specialities
    Health Care

    SEC Form 4 filed by S. Jeffrey Hatfield

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    2/8/21 5:40:28 PM ET
    $MGEN
    Medical Specialities
    Health Care

    $MGEN
    Leadership Updates

    Live Leadership Updates

    View All

    miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team

    Jonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical OfficerViridian is developing VRDN-001 and VRDN-002 for the treatment of thyroid eye diseaseCompany recently licensed exclusive rights from Xencor, Inc. to develop and commercialize therapeutic antibodies targeting IGF-1R incorporating Xtend™ Fc half-life extension technology BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics, Inc. (“Viridian”).   Beginning tomorrow, Viridian will trade on NASDAQ under the ticker symbol "VR

    1/19/21 7:00:00 AM ET
    $MGEN
    Medical Specialities
    Health Care

    $MGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team

    Jonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical OfficerViridian is developing VRDN-001 and VRDN-002 for the treatment of thyroid eye diseaseCompany recently licensed exclusive rights from Xencor, Inc. to develop and commercialize therapeutic antibodies targeting IGF-1R incorporating Xtend™ Fc half-life extension technology BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics, Inc. (“Viridian”).   Beginning tomorrow, Viridian will trade on NASDAQ under the ticker symbol "VR

    1/19/21 7:00:00 AM ET
    $MGEN
    Medical Specialities
    Health Care

    miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease

    Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor’s Xtend™ half-life extension technology miRagen expects to file an Investigational New Drug (IND) application for VRDN-002, including half-life extension, by the end of 2021 BOULDER, Colo., Dec. 17, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced an agreement under which miRagen gains exclusive rights to develop and commercialize therapeutic antibodies targeting IGF-1R incorporating Xtend™ Fc technology from Xencor, Inc. This clinically validated technology p

    12/17/20 7:00:00 AM ET
    $MGEN
    Medical Specialities
    Health Care

    $MGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Miragen Therapeutics, Inc.

    SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

    3/15/21 4:38:22 PM ET
    $MGEN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed

    SC 13G - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

    3/10/21 7:17:41 AM ET
    $MGEN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed

    SC 13G - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

    2/19/21 8:02:11 AM ET
    $MGEN
    Medical Specialities
    Health Care

    $MGEN
    SEC Filings

    View All

    SEC Form 8-K filed

    8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)

    1/20/21 8:01:58 AM ET
    $MGEN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed

    SC 13G - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

    1/19/21 4:18:23 PM ET
    $MGEN
    Medical Specialities
    Health Care

    SEC Form 4 filed by Stuart William Marshall

    4 - MIRAGEN THERAPEUTICS, INC. (0001590750) (Issuer)

    1/15/21 7:47:57 PM ET
    $MGEN
    Medical Specialities
    Health Care